Skip to main content

Table 2 Clinical findings in the treatment and control group post-treatment

From: Safety of concurrent treatment of dogs with fluralaner (Bravecto™) and milbemycin oxime - praziquantel

 

Number of dogs affected

 

Treatment group*

Control group**

Single small and mild skin lesions (scar/papilloma/sore spots/alopecia/erythema/laceration/graze/scab/scaling)

4

7

Small amount of serous eye discharge

2

1

Sinus arrhythmia

1: day 28

(1: day -7)

Loose feces with normal feces

1: day 7

0

Others

1 excess ear wax, 2 dental tartar

1 penile discharge, 1 dental tartar, 1 transient limping

  1. *None of these observations was considered to be treatment related, because a similar incidence occurred in the control group, they were already observed pre-treatment and/or the long interval between treatment and occurrence. All observations were common findings in a dog colony.
  2. **None of these observations was considered to be treatment related, because they were already observed pre-treatment and/or are common findings in a dog colony.
Back to article page

Parasites & Vectors

ISSN: 1756-3305

Contact us